Korea’s Bukwang To Sell Hepatitis B Drug In Philippines, Plans Launches In U.S., Europe
This article was originally published in PharmAsia News
Executive Summary
SEOUL - South Korea's Bukwang Pharmaceutical will begin selling its chronic hepatitis B drug Levovir (clevudine) in the Philippines in June, and plans to eventually launch the product across Asia, the U.S. and Europe, according to a company executive
You may also be interested in...
Korea's Yuhan Signs Deal To Sell Gilead's Viread In Korea
SEOUL - South Korea's Yuhan Corp. said it signed an agreement March 30 with Gilead Sciences Inc. to sell the latter's hepatitis B drug Viread (tenofovir) in Korea, beginning in the second half of this year after winning approval from Korea FDA
Korea's Yuhan Signs Deal To Sell Gilead's Viread In Korea
SEOUL - South Korea's Yuhan Corp. said it signed an agreement March 30 with Gilead Sciences Inc. to sell the latter's hepatitis B drug Viread (tenofovir) in Korea, beginning in the second half of this year after winning approval from Korea FDA
Korean Govt Asks MNCs For More Hepatitis A Vaccines
SEOUL - Alarmed by the rapidly rising demand for hepatitis A vaccines to treat students and office workers with the virus, South Korea's Center for Disease Control and Prevention is calling on four multinational companies to bring more vaccines to Korea